[1] 范建高,朱军,李新建,等. 上海市成人脂肪肝患病率及其危险因素流行病学调查. 中华肝脏病杂志,2005,13:9-14.
[2] Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol,2007,13:6419-6424.
[3] Fung J, Lee CK, Chan M, et al. High prevalence of non-alcoholic fatty liver disease in the Chinese-results from the Hong Kong liver health census. Liver Int,2015,35:542-549.
[4] Lu Z, Shao Z, Li Y, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study. World J Gastroenterol,2016,22:3663-3669.
[5] Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab,2013,98:3637-3643.
[6] 李卫东,傅坤发,连燕舒,等. 非酒精性脂肪肝与新发2型糖尿病关系的队列研究. 中华肝脏病杂志,2015,23:675-679.
[7] Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut,2016,65:1359-1368.
[8] Koehler EM, Plompen EP, Schouten JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology,2016,63:138-147.
[9] Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology,2005,41:1313-1321.
[10] Angulo P, Kleiner DE, Dam-Larsen S, et al.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology,2015,149:389-397.
[11] Ekstedt M, Hagstrom H, Nasr P, et al.Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology,2015,61:1547-1554.
[12] Uygun A, Kadayifci A, Isik AT, et al.Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther,2004,19:537-544.
[13] Idilman R, Mizrak D, Corapcioglu D, et al.Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther,2008,28:200-208.
[14] Haukeland JW, Konopski Z, Eggesbo HB, et al.Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol,2009,44:853-860.
[15] Shields WW, Thompson KE, Grice GA, et al.The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroen-terol,2009,2:157-163.
[16] Lavine JE, Schwimmer JB, Van Natta ML, et al.Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA,2011,305:1659-1668.
[17] Fujita K, Iwama H, Miyoshi H, et al.Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol,2016,22:6100-6113.
[18] Rotman Y, Sanyal AJ.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut,2016,66:180-190.
[19] Musso G, Gambino R, Cassader M, et al.A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology,2010,52:79-104.
[20] Ratziu V, Giral P, Jacqueminet S, et al.Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology,2008,135:100-110.
[21] Ratziu V, Charlotte F, Bernhardt C, et al.Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology,2010,51:445-453.
[22] Sanyal AJ, Chalasani N, Kowdley KV, et al.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med,2010,362:1675-1685.
[23] Cusi K, Orsak B, Bril F, et al.Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med,2016,165:305-315.
[24] Lincoff A M, Wolski K, Nicholls SJ, et al.Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA,2007,298:1180-1188.
[25] Lee M, Saver JL, Liao HW, et al.Pioglitazone for secondary stroke prevention: A systematic review and meta-analysis. Stroke,2017,48:388-393.
[26] Rinella ME.Nonalcoholic fatty liver disease: a systematic review. JAMA,2015,313:2263-2273.
[27] Ratziu V, Caldwell S, Neuschwander-Tetri BA.Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology,2010,52:2206-2215.
[28] Lewis JD, Habel LA, Quesenberry CP, et al.Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA,2015,314:265-277.
[29] Tuccori M, Filion KB, Yin H, et al.Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ,2016,352:i1541.
[30] Gupta NA, Mells J, Dunham RM, et al.Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology,2010,51:1584-1592.
[31] Tang A, Rabasa-Lhoret R, Castel H, et al.Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: A randomized trial. Diabetes Care,2015,38:1339-1346.
[32] Petit JM, Cercueil JP, Loffroy R, et al.Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira-NAFLD Study. J Clin Endocrinol Metab,2017,102:407-415.
[33] Smits MM, Tonneijck L, Muskiet MHA, et al.Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia,2016,59:2588-2593.
[34] Armstrong MJ, Gaunt P, Aithal GP, et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet,2016,387:679-690.
[35] Macauley M, Hollingsworth KG, Smith FE, et al.Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab,2015,100:1578-1585.
[36] Cui J, Philo L, Nguyen P, et al.Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J Hepatol,2016,65:369-376.
[37] Joy TR, Mckenzie CA, Tirona RG, et al.Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol,2017,23:141-150.
[38] Deng XL, Ma R, Zhu H X, et al.Short article: A randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol,2017,29:297-301.
[39] Chalasani N, Younossi Z, Lavine JE, et al.The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology,2012,55:2005-2023.
[40] Day P, Dufour JF, Canbay A, et al.EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol,2016,64:1388-1402. |
